DREADD
Designer receptors exclusively activated by designer drugs (DREADDs) are genetically engineered GPCRs that are activated by physiologically inert synthetic small molecules (designer drugs) but not their endogenous ligand. Read our DREADDs mini-review or for practical advice on using these ligands in the lab see Stability of Water-Soluble DREADD Ligands in Solution: A Technical Review and Clozapine N-Oxide (freebase) - a technical review on stability, solubility and use in the lab).
Olanzapine (HB1786)
Description:5-HT2A and D2 antagonist. Potent DREADD agonist. Atypical antipsychotic.
Purity:>99%
- Description:
LPA1 and LPA2 agonist. Inhibits differentiation of neural stem cells (NSCs) into neurons.
Purity:>95%
-
O-Phospho-L-serine (HB0475)
Description:Group III mGlu agonist. Increases stem cell neurogenesis.
Purity:>98%
-
Orexin A (human, rat, mouse) (HB2937)
Description:Excitatory neuropeptide at orexin OX1/OX2 receptors
-
-
-
PD 102807 (HB1509)
Description:Potent, selective M4 receptor antagonist. Promotes erythroid progenitors expansion.
Purity:>98%
-
Perlapine (HB4889)
Description:Effective agonist for muscarinic-based DREADDs in vitro and in vivo. Non-CNO chemogenetic actuator
Purity:>98%
